Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q2 2013 · 10-Q
Revenue$1.10M$1.10M+114.2% vs Q2 2012 Net Income-$23.75K-$23.75KderivedN/M vs Q2 2012 EPS Diluted$0.01$0.01N/M vs Q2 2012 Gross Profitderived$385,860—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Income$354,121N/M Operating Cash Flowderived-$112,946N/M Free Cash Flowderived-$112,946N/M Margins · derivedGross margin34.9%
Operating margin32.1%+46.9 pt vs Q2 2012
Net margin-2.2%+12.6 pt vs Q2 2012
ended Jun 30, 2013 · filed Aug 12, 2013 · 43 d after period end